Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

Fintel reports that on August 5, 2025, Jefferies downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX) from Buy ...

The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

LAVA Therapeutics N.V. (NASDAQ:LVTX) saw its stock rise 4.2% following news of a share purchase agreement with XOMA Royalty ...

Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical ...

Under the terms of the agreement, XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) representing 75% of net proceeds ...

LAVA Therapeutics (LVTX) stock gains as XOMA Royalty (XOMA) agrees to acquire the company for up to $1.24/share plus contingent value rights. Read more here.

Xoma Royalty has agreed to acquire Lava Therapeutics.